Loading…
Lobbying Spend
—
Filings
14
Firms Hired
1
Active Period
2023–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
2026 · third_quarter · Firm: OGR
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act; H.R.5178, Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.1796
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act; H.R.5178, Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.5178
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
2026 · second_quarter · Firm: OGR
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act; H.R.5178, Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.1796
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act; H.R.5178, Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.5178
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
2026 · first_quarter · Firm: OGR
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act; H.R.5178, Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.1796
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act; H.R.5178, Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.5178
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
2025 · fourth_quarter · Firm: OGR
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
2025 · third_quarter · Firm: OGR
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
2025 · second_quarter · Firm: OGR
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.1796
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.7432, Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.7432
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.7432, Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.7432
Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.7432, Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R.7432
Source: Senate LDA